Science Corp’s $400M Series D Values Brain Tech at $3.5B as Anti-Blindness Push Accelerate

Science Corp. has raised $400 million in a Series D round, giving the company a $3.5 billion valuation as it expands its work on treatments for blindness. The funding follows years of research into retinal gene therapy and neural repair, putting Science Corp. in a competitive space where clinical progress and regulatory approval remain major challenges.
The round comes at a time when European tech funding has rebounded, with €2.3 billion raised across more than 60 deals last week, according to *tech.eu*. Still, deeptech investments remain concentrated in areas where the science is well-established and the path to market is clear. Its valuation suggests investors believe the company can overcome both scientific and commercial obstacles in degenerative eye diseases—a field where few have achieved success at scale.
Global medtech valuations have risen for companies with strong clinical progress, though Science Corp. hasn’t shared specific milestones tied to this funding. The question now is whether Science Corp. can follow the regulatory and reimbursement strategies of earlier players or if its valuation will depend on proving its approach works where others have faced setbacks.
Unlike broader biotech trends, this isn’t about speculation—it’s about whether Science Corp. can deliver in a field where failure carries high costs.
Sources: techcrunch.com
“This funding shows how investors are still backing high-risk medtech startups with clear scientific and commercial paths—even as venture capital dries up in other areas.”
One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.
Read the original reporting
The outlets below did the original reporting.
Related briefs
- India’s AI Funding Boom Hides a Critical Weakness: Can It Build a Foundational Player?
- BrightAI raises $97M to expand AI-driven industrial monitoring with GE Vernova partnership
- K4Connect Raises $8M to Build AI Agents for Senior Living Workflows
- IntelliProve raises €2.7M to turn smartphones into robot health monitors
- Wallenberg Investments backs Algoryx as Swedish deeptech sees elite capital influx
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.